|Articles|October 12, 2021

Contagion

  • Contagion, October 2021 (Vol. 06, No. 5)
  • Volume 6
  • Issue 5

Time to Prepare People to Accept COVID-19 Endemicity

SARS-CoV-2 has taken us on a rollercoaster, and not just on graphs of case counts. The natural tendency to project linearity to trends makes each hill and dip feel unnatural. The media exacerbates perceptual changes with its hyperfocal attention on each new development, even expected ones like breakthrough infections. People feel they are being jolted around.

The early efficacy results of the mRNA vaccines from Pfizer-BioNTech and Moderna were positively stunning. Demonstrating more than 90% vaccine effectiveness against symptomatic infection when the goal was a 50% reduction in severe disease caught people off guard. It was the first bit of good news in quite a while, coming at a time when school buildings were shut in much of the country and we adapted to e-school, working from home, and the awkwardness of Zoom happy hours. When vaccines started to be given in December 2020, people began to envision a world without COVID-19.

Things have not turned out that way. Despite commanding the greatest portion of vaccine supply and getting a head start, vaccinations in the US have fallen behind that of most high-income countries; at this writing, the US is at the bottom of the G7 and 60th in the world in percentage vaccinated. However, that is only part of the picture. The virus has not waited for us to vaccinate the world’s population- it keeps evolving towards more transmissible variants. In the Delta variant, SARS-CoV-2 has transformed into not just a highly transmissible variant, but one of the world’s most transmissible infectious diseases. We are fortunate that Delta came to the US after vaccines became widely available or we would be looking at a very different society right now.

The combination of Delta and vaccine hesitancy has cost many lives, but it also highlights the need to reset expectations on the COVID-19 endgame. Herd immunity may never have been a realistic goal, but it seems clear it is an impossibility. Over the next several years, everyone is likely to be infected with SARS-CoV-2. With the attenuation that vaccination provides, most vaccinated people will have asymptomatic, mild, or moderate infection. Unvaccinated people with previous COVID-19 will have less severe reinfection, and the ever-decreasing number of unvaccinated people without previous COVID-19 will be susceptible to severe disease.

The continued spread of immunity, whether acquired by vaccination or infection, will drive overall cases down. However, the incomplete nature of immunity and future mutations in SARS-CoV-2 will allow it to remain a circulating human pathogen like other endemic human coronaviruses.

One of the most apparent issues that the pandemic has revealed is ineffective communication. To increase vaccine uptake, ‘get vaccinated and you’re good’ became the narrative. People listened. When Delta became pervasive and changed things again, momentum towards a ‘post-pandemic’ dream was harder to change. Therefore, it is time to prepare people for a future with endemic COVID-19 now. We won’t be masked forever, but we aren’t wiping the virus off the earth either.


Related to this article

Pfizer 25-Valent Pneumococcal Vaccine Boosts Serotype 3 Response in Infants
Alejandra Gurtman, MD, discussed the phase 2 data at IDWeek 2026 which showed the investigational 25-valent pneumococcal conjugate vaccine 25vPnC produced serotype 3 antibody levels about 15-fold higher than Prevnar 20 after the booster dose, targeting a serotype still behind 10.6% of invasive pneumococcal disease in US children younger than five years.
Measles Update: October 23, 2026
The latest CDC numbers show a 4.0% increase in measles cases from week-to-week, bringing the 2026 US total to 4588 confirmed cases. Ninety-six percent of cases are outbreak-associated.
Inhaled Amikacin Shows Low Resistance Rates in MAC Lung Disease in ENCORE
In the phase 3b ENCORE trial, adding amikacin liposome inhalation suspension (ALIS) to azithromycin and ethambutol significantly improved culture conversion in newly diagnosed MAC lung disease, while treatment-emergent amikacin (2.2%) and macrolide (1.1%) resistance stayed rare. Kevin Winthrop, MD, provides insights around the study.
Measles Update: October 16, 2026
The latest CDC numbers show an 8.1% increase in measles cases from week-to-week, bringing the 2026 US total to 4410 confirmed cases. A CDC disease detective is going to Pennsylvania to aid in the state's massive outbreak, and the agency reports on a rare measles complication that is uniformly fatal.
Cefiderocol Continues to Show Activity Against Resistant Gram-Negative Infections
Shionogi data presented at IDWeek 2026 demonstrated a 76.7% clinical response with cefiderocol in carbapenem-resistant respiratory infections and high in vitro activity against resistant P aeruginosa VAP isolates. Christine Slover, PharmD, vice president, Infectious Diseases US Medical Affairs, Shionogi, offers insights on the data as well as clinical considerations for providers when weighing the antibiotic for patients.